AbbVie (NYSE:ABBV) Shares Down 2.4% – Here’s Why

AbbVie Inc. (NYSE:ABBV)’s stock price fell 2.4% during mid-day trading on Thursday . The company traded as low as $215.83 and last traded at $216.6550. 6,154,733 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 7,418,281 shares. The stock had previously closed at $221.89.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Calico completed a Phase 1 trial for ABBV‑CLS‑616, advancing a pipeline program that supports longer‑term growth expectations. AbbVie Quietly Advances ABBV‑CLS‑616
• Positive Sentiment: AbbVie completed a first‑in‑human trial for GUB014295 (an obesity candidate), signaling progress in its obesity push — a market management expects to be a major growth driver. AbbVie Advances Obesity Pipeline
• Positive Sentiment: AbbVie said it will build out its presence in the obesity market (licensing from Gubra), reinforcing management’s strategy to diversify away from legacy brands. AbbVie plans to build out its presence in obesity market
• Positive Sentiment: AbbVie partnered with RemeGen on a novel bispecific antibody for advanced tumors, expanding its oncology footprint after recent deal activity. AbbVie, RemeGen Partner on Novel Bispecific Antibody
• Positive Sentiment: At JPM, AbbVie presented a “clear line of sight” to growth into the 2030s — messaging that supports longer‑term revenue expectations and investor confidence. JPM26, Day 3: AbbVie touts ‘clear line of sight’
• Positive Sentiment: AbbVie struck a White House drug‑pricing deal that includes a $100B U.S. investment pledge and won tariff relief — lowers some cost risks and improves regulatory relations. AbbVie inks latest White House drug pricing deal
• Neutral Sentiment: Unusual options activity: investors bought ~477,943 call contracts today (a ~2,599% jump vs. typical call volume). This heavy call flow can reflect bullish speculation or complex hedging and often increases intraday volatility rather than providing a clear directional signal.
• Neutral Sentiment: Analyst commentary and conference transcript coverage show mixed but generally optimistic views from Wall Street; media coverage may amplify short‑term trading moves. Wall Street Bulls Look Optimistic About AbbVie
• Neutral Sentiment: Full JPM presentation transcript available for deeper read on strategy and financials. AbbVie Presents at J.P. Morgan Healthcare Conference Transcript

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $258.00 price target on shares of AbbVie in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $247.84.

AbbVie Trading Down 2.4%

The stock has a market capitalization of $382.91 billion, a price-to-earnings ratio of 164.13, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The firm’s fifty day moving average price is $226.94 and its 200 day moving average price is $216.08.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Institutional Trading of AbbVie

Several hedge funds have recently made changes to their positions in ABBV. Vanguard Group Inc. grew its stake in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after acquiring an additional 448,554 shares in the last quarter. Geode Capital Management LLC boosted its holdings in AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. grew its stake in AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares in the last quarter. Norges Bank purchased a new stake in AbbVie during the 2nd quarter worth about $4,288,200,000. Finally, Legal & General Group Plc increased its holdings in AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after purchasing an additional 493,420 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.